Hopp til innhold

Onkologi

Behandling av anemi

Erytropoiese-stimulerende midler

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (åpner nytt vindu)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Kilde‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Arkiv‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (åpner nytt vindu)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (åpner nytt vindu)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Kilde‎: Acta Haematol 2007;117(3):162-7.

Arkiv‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (åpner nytt vindu)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (åpner nytt vindu)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Kilde‎: Am J Hematol 2013;88(12):990-6.

Arkiv‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (åpner nytt vindu)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (åpner nytt vindu)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Kilde‎: J Clin Oncol 2011;29(28):3791-7.

Arkiv‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (åpner nytt vindu)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (åpner nytt vindu)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Kilde‎: Cancer 2012;118(3):848-55.

Arkiv‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (åpner nytt vindu)

Management of anemia in cancer patients. (åpner nytt vindu)

Calabrich A, Katz A.

Kilde‎: Future Oncol 2011;7(4):507-17.

Arkiv‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (åpner nytt vindu)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (åpner nytt vindu)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Kilde‎: BJU Int 2011;108(10):1582-7.

Arkiv‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (åpner nytt vindu)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (åpner nytt vindu)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Kilde‎: J Clin Oncol 2010;28(13):2239-45.

Arkiv‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (åpner nytt vindu)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (åpner nytt vindu)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Kilde‎: Br J Cancer 2011;105(9):1267-72.

Arkiv‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (åpner nytt vindu)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (åpner nytt vindu)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Kilde‎: J Intern Med 2017;281(3):284-99.

Arkiv‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (åpner nytt vindu)

How I treat cancer-associated anemia. (åpner nytt vindu)

Gilreath JA, Rodgers GM

Kilde‎: Blood 2020;136(7):801-13.

Arkiv‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (åpner nytt vindu)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (åpner nytt vindu)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Kilde‎: Eur J Haematol. 2023 110(4):354-61.

Arkiv‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (åpner nytt vindu)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (åpner nytt vindu)

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

Kilde‎: Int J Hematol 2015;102(4):401-12.

Arkiv‎: PubMed 26323997

DOI‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 (åpner nytt vindu)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (åpner nytt vindu)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Kilde‎: Cancer 2013;119(1):107-14.

Arkiv‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (åpner nytt vindu)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (åpner nytt vindu)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Kilde‎: J Natl Cancer Inst 2013;105(14):1018-26.

Arkiv‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (åpner nytt vindu)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (åpner nytt vindu)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Kilde‎: Cancer Sci 2013;104(4):481-5.

Arkiv‎: PubMed 23331490

DOI‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (åpner nytt vindu)

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (åpner nytt vindu)

Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, Fenaux P

Kilde‎: Br J Haematol 2019;184(2):134-60.

Arkiv‎: PubMed 30549002

DOI‎: 10.1111/bjh.15707

https://www.ncbi.nlm.nih.gov/pubmed/30549002 (åpner nytt vindu)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (åpner nytt vindu)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Kilde‎: Support Care Cancer 2012;20(1):159-65.

Arkiv‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (åpner nytt vindu)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (åpner nytt vindu)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Kilde‎: Leuk Lymphoma. 2019;60(9):2324-7.

Arkiv‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (åpner nytt vindu)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (åpner nytt vindu)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Kilde‎: Oncologist 2010;15(9):935-43.

Arkiv‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (åpner nytt vindu)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (åpner nytt vindu)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Kilde‎: Lung Cancer 2012;76(3):478-85.

Arkiv‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (åpner nytt vindu)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (åpner nytt vindu)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Kilde‎: Eur J Haematol 2016;97(1):33-8.

Arkiv‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (åpner nytt vindu)

Intravenøse jernpreparater

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (åpner nytt vindu)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Kilde‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Arkiv‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (åpner nytt vindu)

Intravenous iron in oncology. (åpner nytt vindu)

Auerbach M, Ballard H.

Kilde‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Arkiv‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (åpner nytt vindu)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (åpner nytt vindu)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Kilde‎: Int J Colorectal Dis 2016;31(3):543-51.

Arkiv‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (åpner nytt vindu)

How I treat cancer-associated anemia. (åpner nytt vindu)

Gilreath JA, Rodgers GM

Kilde‎: Blood 2020;136(7):801-13.

Arkiv‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (åpner nytt vindu)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (åpner nytt vindu)

Gilreath JA, Stenehjem DD, Rodgers GM.

Kilde‎: J Natl Compr Canc Netw 2012;10(5):669-76.

Arkiv‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (åpner nytt vindu)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (åpner nytt vindu)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Kilde‎: Eur J Haematol. 2023 110(4):354-61.

Arkiv‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (åpner nytt vindu)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (åpner nytt vindu)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Kilde‎: Curr Oncol. 2023 24;30(9):7836-51.

Arkiv‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (åpner nytt vindu)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (åpner nytt vindu)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Kilde‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Arkiv‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (åpner nytt vindu)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (åpner nytt vindu)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Kilde‎: World J Gastroenterol 2014;20(8):1972-85.

Arkiv‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (åpner nytt vindu)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (åpner nytt vindu)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Kilde‎: South Asian J Cancer. 2023 15;12(2):93-9.

Arkiv‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (åpner nytt vindu)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (åpner nytt vindu)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Kilde‎: J Clin Oncol 2008;26(10):1619-25.

Arkiv‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (åpner nytt vindu)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (åpner nytt vindu)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Kilde‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

Arkiv‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (åpner nytt vindu)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (åpner nytt vindu)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Kilde‎: Ann Oncol 2013;24(2):475-82.

Arkiv‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (åpner nytt vindu)

ONKOLOGI
Behandling av anemi
Norsk
Behandling av anemi
https://assetsnffrgf-a.akamaihd.net/assets/ct/5a91b826b0/images/syn_placeholder_sqr.png

Kontakt lokal representant for sykehuskontaktutvalget

En gratis global tjeneste som er tilgjengelig 24 timer i døgnet for klinikere som behandler Jehovas vitner.

Kontakt

Medisinsk informasjonsmateriale

Aktuelle emner: Kliniske strategier for å behandle blodtap og anemi uten blodtransfusjoner, Jehovas vitners religiøse og etiske standpunkt i spørsmål om medisinsk behandling, og de tjenester Jehovas vitner tilbyr medisinsk personell gjennom sitt globale nettverk av sykehuskontaktutvalg.

Se nedlastinger

Videoer

Alternative behandlingsmåter og medisinske og etiske betraktninger for klinikere som behandler Jehovas vitner.

Se videoer